Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ovid Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Ovid Therapeutics Inc.’s stock price such as:

• Ovid Therapeutics Inc.’s current stock price and volume
• Why Ovid Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for OVID from analysts
• OVID’s stock price momentum as measured by its relative strength

About Ovid Therapeutics Inc. (OVID)

Before we jump into Ovid Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Want to learn more about Ovid Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ovid Therapeutics Inc..

Ovid Therapeutics Inc.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, Ovid Therapeutics Inc.’s stock price was $2.800.

Ovid Therapeutics Inc. is up 2.19% from its previous closing price of $2.740.

During the last market session, Ovid Therapeutics Inc.’s stock traded between $2.710 and $2.830. Currently, there are approximately 197.45 million shares outstanding for Ovid Therapeutics Inc..

Ovid Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Ovid Therapeutics Inc. Stock Price History

Ovid Therapeutics Inc.’s (OVID) price is currently up 26.13% so far this month.

During the month of August, Ovid Therapeutics Inc.’s stock price has reached a high of $2.950 and a low of $2.222.

Over the last year, Ovid Therapeutics Inc. has hit prices as high as $3.105 and as low as $0.940. Year to date, Ovid Therapeutics Inc.’s stock is up 71.78%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ovid Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there were 0 analysts who downgraded Ovid Therapeutics Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Ovid Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ovid Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ovid Therapeutics Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ovid Therapeutics Inc. (OVID) by visiting AAII Stock Evaluator.

Relative Price Strength of Ovid Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, Ovid Therapeutics Inc. has a weighted four-quarter relative price strength of 23.00%, which translates to a Momentum Score of 93 and is considered to be Very Strong.

Want to learn more about how Ovid Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ovid Therapeutics Inc. Stock Price: Bottom Line

As of August 21, 2026, Ovid Therapeutics Inc.’s stock price is $2.800, which is up 2.19% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ovid Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.